Logo for LaunchBio Program: Investor ConnectLogo for LaunchBio Program: Investor Connect

Bridging the Gap Between Innovation and Capital

Online

Global Brain

Focus on preclinical, therapeutic, medical device and AI companies

Program

Calling all early stage biotech, preclinical therapeutic, diagnostic, medical device and AI companies!

Global Brain is an independent venture capital firm that aims to bring new industries to the society through extensive hands-on support for startups and open innovation with large corporations. Their mission is to “bring unimaginable innovation into society through business creation.” Global Brain’s deal count is among the best in the world. In 2022, they invested a total of JPY 28.8 billion in 150 deals, which was a company record high.

Event

LaunchBio and Silicon Valley Bank, a division of First Citizens Bank, are pleased to announce their next Investor Connect virtual event with Global Brain. Global Brain investments are focused on potentially transformative therapeutics, with an emphasis in core therapeutic areas: Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease, and Vaccines. They will consider platform technologies, diagnostics, drug delivery, pharmaceutical services, and other technologies that have the potential to transform drug discovery and development. Pure platform startups with high-throughput drug discovery technologies; including, but not limited to, AI/ML.

Applications will be selected based on meeting the following criteria:

Geography:
Not restricted.

Company type:
Early stage life science biotech companies developing therapeutics, medical devices or AI.

Milestones anticipated:

  • Inflammation & Immunology, Internal Medicine, Oncology, Anti-Infectives, and Vaccines
  • Asset-focused therapeutic companies with strong in vivo data.
  • Platform-focused therapeutic companies with disruptive technology, to validate and expand platforms and nominate lead assets.
  • Companies addressing large unmet medical needs and markets with strong in vivo data, to fund design, manufacturing, and clinical testing.


Stage:
Companies seeking pre-seed, seed, series A. Qualifying start-ups can apply here today.

Applications are accepted on a rolling basis. Learn more about LaunchBio’s Investor Connect series, in partnership with Silicon Valley Bank, a division of First Citizens Bank.